Companies

See how salaries can vary from company to company

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) in the United States and Poland. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneou... view company details

A Full Spectrum of Housing Services Under One Roof Whether you're looking for professional property management, construction management services, new project financing, or a joint venture development partner, The John Stewart Company can guide you through the complex process of multi-family real estate financing, development, marketing and management. We have the versatility and professional capacity to perform every task from initial feasibility through development and long-term property management. We serve our customers with 1,000 employees in five offices across California. Our management ... view company details

Soliant Consulting® is a consulting and development partner for custom software applications. We help clients anticipate the future of their businesses and build powerful digital solutions to keep them ahead of the game. As consultants, we concentrate on what to build and why, and our seasoned project managers ensure clients understand our process every step of the way. We empower them through digital transformation strategies, legacy system modernization, web portal development, and custom software architecture. Through our role as a Salesforce Partner, we help clients increase their return o... view company details

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a colla... view company details

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinic... view company details

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery system for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase IIB clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase IIa clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary di... view company details

BAO Systems is an industry leader in digital data solutions for health and development. We empower our partners to implement scalable and sustainable solutions that uncover data-driven insights to improve livelihoods, strengthen health systems, and achieve equitable human development. Our team is comprised of passionate public health and development practitioners, information system experts, software engineers, system engineers, monitoring and evaluation advisors, and data scientists. Our team excels in providing a broad spectrum of solutions around data collection, management, integration and... view company details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treat... view company details

Comstock Holding Companies, Inc. operates as a real estate development and services company primarily in the mid-Atlantic region, the United States. It operates through three segments: Homebuilding, Asset Management, and Real Estate Services. The company builds multi-family units, single-family homes, townhouses, mid-rise and high-rise condominiums, and mixed-use developments. It also provides real estate management services, including strategic planning, land development, entitlement, property management, sales and marketing, workout and turnaround strategies, financing, and general construct... view company details

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver diseas... view company details

FRP Holdings, Inc., through its subsidiaries, engages in various real estate businesses in the United States. The company operates through four segments: Asset Management, Mining Royalty Lands, Development, and Stabilized Joint Venture. The Asset Management segment owns, leases, and manages commercial properties. The Mining Royalty Lands segment owns various properties comprising approximately 15,000 acres under lease for mining rents or royalties primarily in Florida, Georgia, and Virginia. The Development segment owns and monitors the use of parcels of land that are in various stages of deve... view company details

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinica... view company details

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indicat... view company details

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prost... view company details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastropar... view company details

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an ... view company details

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute mye... view company details

Appvion creates product solutions through its development and use of coating formulations and applications. The Company produces thermal, carbonless, security, inkjet, digital specialty and colored papers. Appvion is headquartered in Appleton, Wisconsin, has manufacturing operations in Wisconsin and Pennsylvania. view company details

Artis, LLC conducts research and development primarily for government clients such as DARPA, ONR, NVESD, CDC and ARL. Current areas of research include active protection systems, advanced low power sensors, embedded systems, autonomous highway safety systems and 3D imaging sensors. view company details

Canterbury Park Holding Corporation hosts pari-mutuel wagering on horse races and unbanked card games at its Canterbury park racetrack and card casino facility in Shakopee, Minnesota. The company operates through four segments: Horse Racing, Card Casino, Food and Beverage, and Development. The Horse Racing segment operates year-round simulcasting of horse races and wagering on live thoroughbred; and quarter horse races on a seasonal basis. The Card Casino segment offers unbanked card games, such as poker and table games. The Food and Beverage segment operates concession stands, restaurants and... view company details